Bioventus Operating Expenses 2018-2024 | BVS

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Bioventus operating expenses from 2018 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Bioventus operating expenses from 2018 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Related Stocks
Company Name	Market Cap
Zoetis (ZTS)	$89B
Takeda Pharmaceutical (TAK)	$47.2B
Merck (MKGAF)	$23.7B
Astellas Pharma (ALPMY)	$22.1B
Summit Therapeutics (SMMT)	$17.8B
Sandoz Group AG (SDZNY)	$17.6B
United Therapeutics (UTHR)	$15.2B
Shionogi (SGIOY)	$13.1B
Neurocrine Biosciences (NBIX)	$12.1B
Catalent (CTLT)	$10.9B
Orion OYJ (ORINY)	$7.4B
Revolution Medicines (RVMD)	$7.4B
Jazz Pharmaceuticals (JAZZ)	$6.8B
Ionis Pharmaceuticals (IONS)	$6.2B
Hikma Pharmaceuticals Plc (HKMPF)	$5.7B
Madrigal Pharmaceuticals (MDGL)	$5.1B
Corcept Therapeutics (CORT)	$4.4B
Crinetics Pharmaceuticals (CRNX)	$4.2B
Dyne Therapeutics (DYN)	$3.4B
PTC Therapeutics (PTCT)	$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.7B
Arrowhead Pharmaceuticals (ARWR)	$2.6B
Catalyst Pharmaceuticals (CPRX)	$2.4B
Soleno Therapeutics (SLNO)	$2.1B
Recursion Pharmaceuticals (RXRX)	$1.9B
Centessa Pharmaceuticals (CNTA)	$1.8B
BioCryst Pharmaceuticals (BCRX)	$1.6B
Xencor (XNCR)	$1.6B
Harrow (HROW)	$1.6B
Cassava Sciences (SAVA)	$1.5B